Seres Therapeutics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 4.99 M

Seres Therapeutics, Inc. Depreciation And Amortization is USD 4.99 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -43.50% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • Seres Therapeutics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 8.82 M, a 36.60% change year over year.
  • Seres Therapeutics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 6.46 M, a 6.92% change year over year.
  • Seres Therapeutics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 6.04 M, a -3.37% change year over year.
  • Seres Therapeutics, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 6.25 M, a -8.92% change year over year.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased